Cited by 421Erythropoietin and Anemia TreatmentBiosimilars and Bioanalytical MethodsHemoglobin structure and function

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

Open access

Egrie, Joan C, Dwyer, Erik, Browne, Jeffrey K, Hitz, Anna, Lykos, Michele A·2003·Experimental Hematology

Open this paper in CoChat — free account Open PDF

Abstract

Objective Experiments on human erythropoietin (EPO) demonstrated that there is a direct relationship between the sialic acid-containing carbohydrate content of EPO, its circulating half-life, and in vivo bioactivity. This led to the hypothesis that an EPO analogue engineered to contain additional oligosaccharide chains would have enhanced biological activity. Darbepoetin alfa, a hyperglycosylated recombinant human EPO (rHuEPO) analogue with two extra carbohydrate chains, was designed and developed to test this hypothesis. Materials and methods Comparative pharmacokinetic and pharmacodynamic studies and biochemical analyses of darbepoetin alfa and rHuEPO were performed to define the consequences of the increased carbohydrate content. Results Due to its increased sialic acid-containing carbohydrate content, darbepoetin alfa has a higher molecular weight, a greater negative charge, and a approximately fourfold lower EPO receptor binding activity than rHuEPO. It also has a threefold longer circulating half-life than rHuEPO in rats and dogs. In spite of its lower receptor binding, and perhaps counterintuitively, darbepoetin alfa is significantly more potent in vivo than rHuEPO. Due to the pharmacokinetic differences, the relative potency of the two molecules varies as a function of the dosing frequency. Darbepoetin alfa is 3.6-fold more potent than rHuEPO in increasing the hematocrit of normal mice when each is administered thrice weekly, but when the administration frequency is reduced to once weekly, darbepoetin alfa is approximately 13-fold to 14-fold more potent than rHuEPO. Conclusions Increasing the sialic acid-containing carbohydrate content beyond the maximum found in EPO leads to a molecule with a longer circulating half-life and thereby an increased in vivo potency that can be administered less frequently.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0301-472x(03)00006-7

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
THE PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY
Greenwood, F. C., Hunter, W., & GLOVER, J. S. (1963) · Biochemical Journal · doi:10.1042/bj0890114 · Cited by 10,141
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,796
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Hastings, R. C. (1996) · JAMA · doi:10.1001/jama.1996.03540120077042 · Cited by 2,375
Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
Eschbach, J. W., Egrie, J. C., Downing, M. R., Browne, J. K., & Adamson, J. W. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701083160203 · Cited by 1,987
Self-citation
EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSIS
Winearls, C., Pippard, M. J., Downing, M. R., Oliver, D., Reid, C. D. L., & Cotes, P. M. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92192-6 · Cited by 1,401
Applied Biopharmaceutics and Pharmacokinetics.
(1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-94-6-826_2 · Cited by 1,209
Erythropoietin
Krantz, S. B. (1991) · Blood · doi:10.1182/blood.v77.3.419.419 · Cited by 881
Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease: Results of a Phase III Multicenter Clinical Trial
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Self-citation
Expression cloning of the murine erythropoietin receptor
D’Andrea, A. D., Lodish, H. F., & Wong, G. G. (1989) · Cell · doi:10.1016/0092-8674(89)90965-3 · Cited by 737

Show all 47 references

Research works printed but not linked: 1

Sowade, 1998, The safety of treatment with recombinant human erythropoietin in clinical use, Int J Mol Med., 1, 303

Sorted by citations

Items 101–200 of 421

Erythropoiesis stimulating agents approaches to modulate activity
Sinclair, A. M. (2013) · Biologics · doi:10.2147/btt.s45971 · Cited by 41
Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity
Long, D. L., Doherty, D. H., Eisenberg, S. P., Smith, D. J., Rosendahl, M. S., Christensen, K. R., Edwards, D. P., Chlipala, E. A., & Cox, G. N. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.02.011 · Cited by 41
Effect of surfactant pluronic F‐68 on CHO cell growth, metabolism, production, and glycosylation of human recombinant IFN‐γ in mild operating conditions
Clincke, M., Guédon, E., Yen, F. T., Ogier, V., Roitel, O., & Goergen, J. (2010) · Biotechnology Progress · doi:10.1002/btpr.503 · Cited by 43
Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: Effects of darbepoetin alfa on TIMP-1 null and wild-type mice
Thorne, M., Moore, C. S., & Robertson, G. S. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.04.003 · Cited by 40
Darbepoetin versus epoetin
Herrington, J. D. (2005) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050181 · Cited by 40
Impact of N-Linked Glycosylation on Therapeutic Proteins
Chen, B., Liu, W., Li, Y., Ma, B., Shang, S., & Tan, Z. (2022) · Molecules · doi:10.3390/molecules27248859 · Cited by 39
Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role
Agoram, B. M., Aoki, K., Doshi, S., Gegg, C. V., Jang, G. R., Molineux, G., Narhi, L. O., & Elliott, S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21578 · Cited by 39
Current status and perspectives of biopharmaceutical drugs
Ryu, J. K., Kim, H. S., & Nam, D. H. (2012) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-012-0095-1 · Cited by 39
Glycoengineering of CHO Cells to Improve Product Quality
Wang, Q., Yin, B., Chung, C., & Betenbaugh, M. J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6972-2_2 · Cited by 42
Site‐Specific Introduction of Sialic Acid into Insulin
Sato, M., Sadamoto, R., Niikura, K., Monde, K., Kondo, H., & Nishimura, S. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200353058 · Cited by 39
An Extended Terminal Half-Life for Darbepoetin Alfa
Padhi, D., Ni, L., Cooke, B. P., Marino, R., & Jang, G. R. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645050-00005 · Cited by 39
Transforming Growth Factor Beta Receptor 2 (TGFBR2) Changes Sialylation in the Microsatellite Unstable (MSI) Colorectal Cancer Cell Line HCT116
Lee, J., Ballikaya, S., Schönig, K., Ball, C. R., Glimm, H., Kopitz, J., & Gebert, J. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057074 · Cited by 38
The Absorption of Darbepoetin Alfa Occurs Predominantly via the Lymphatics Following Subcutaneous Administration to Sheep
McLennan, D. N., Porter, C. J. H., Edwards, G. A., Heatherington, A. C., Martin, S. W., & Charman, S. A. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9064-8 · Cited by 38
Darbepoetin alfa Administered Every Other Week Maintains Hemoglobin Levels over 52 Weeks in Patients with Chronic Kidney Disease Converting from Once-Weekly Recombinant Human Erythropoietin: Results from Simplify the Treatment of Anemia with Aranesp (STAAR)
Hertel, J., Locay, H. R., Scarlata, D., Jackson, L., Prathikanti, R., & Audhya, P. (2006) · American Journal of Nephrology · doi:10.1159/000092852 · Cited by 38
Glycoengineering Chinese hamster ovary cells: a short history
Donini, R., Haslam, S. M., & Kontoravdi, C. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200840 · Cited by 37
Analytical Platform for Glycomic Characterization of Recombinant Erythropoietin Biotherapeutics and Biosimilars by MS
Oh, M. J., Hua, S. S., Kim, B. J., Jeong, H. N., Jeong, S. H., Grimm, R., Yoo, J. S., & An, H. J. (2013) · Bioanalysis · doi:10.4155/bio.12.327 · Cited by 37
Capillary electrophoresis and matrix‐assisted laser desorption/ionization‐time of flight‐mass spectrometry for analysis of the novel erythropoiesis‐stimulating protein (NESP)
Sanz‐Nebot, V., Benavente, F., Giménez, E., & Barbosa, J. (2005) · Electrophoresis · doi:10.1002/elps.200410092 · Cited by 37
An open‐label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis
Agarwal, A. K., Silver, M. R., Reed, J., Dhingra, R. K., Liu, W., Varma, N., & Stehman-Breen, C. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01723.x · Cited by 37
Anaemia in cancer patients: pathophysiology, incidence and treatment
Bokemeyer, C., Oechsle, K., & Hartmann, J. T. (2005) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2005.01527.x · Cited by 36
Population pharmacokinetics of darbepoetin alfa in healthy subjects
Agoram, B. M., Sutjandra, L., & Sullivan, J. T. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02752.x · Cited by 35
Recombinant human erythropoietin in oncology: current status and further developments
Engert, A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi307 · Cited by 36
The Effect of Erythropoietin and Its Derivatives on Ischemic Stroke Therapy: A Comprehensive Review
Ma, Y., Zhou, Z., Yang, G., Ding, J., & Wang, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.743926 · Cited by 35
Development and Analysis of Alpha 1-Antitrypsin Neoglycoproteins: The Impact of AdditionalN-Glycosylation Sites on Serum Half-Life
Lusch, A., Kaup, M., Marx, U., Tauber, R., Blanchard, V., & Berger, M. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400043r · Cited by 34
Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations of Existing Therapies
Wish, J. B., & Coyne, D. W. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1371 · Cited by 34
Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease
Warady, B. A., & Silverstein, D. M. (2013) · Pediatric Nephrology · doi:10.1007/s00467-013-2557-x · Cited by 33
Natural Form of Noncytolytic Flexible Human Fc as a Long-Acting Carrier of Agonistic Ligand, Erythropoietin
Im, S. J., Yang, S. I., Yang, S. H., Choi, D. H., Choi, S. Y., Kim, H. S., Jang, D. S., Jin, K. S., Chung, Y.-K., Kim, S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024574 · Cited by 33
Biosimilars: Practical Considerations for Pharmacists
Stevenson, J. G., Popovian, R., Jacobs, I. A., Hurst, S. I., & Shane, L. G. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017690743 · Cited by 33
Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing
Weng, Y., Ishino, T., Sievers, A., Talukdar, S., Chabot, J., Tam, A. S. P., Duan, W., Kerns, K. M., Sousa, E. A., He, T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22456-w · Cited by 33
Analysis of recombinant human erythropoietin and novel erythropoiesis stimulating protein digests by immunoaffinity capillary electrophoresis–mass spectrometry
Giménez, E., Benavente, F., de Bolós, C., Nicolás, E., Barbosa, J., & Sanz‐Nebot, V. (2009) · Journal of Chromatography A · doi:10.1016/j.chroma.2009.01.057 · Cited by 33
Drug-induced and antibody-mediated pure red cell aplasia: A review of literature and current knowledge
Smalling, R., Foote, M., Molineux, G., Swanson, S. J., & Elliott, S. (2004) · Biotechnology annual review · doi:10.1016/s1387-2656(04)10008-2 · Cited by 33
Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: Time to reach the full therapeutic potential of erythropoietin
Konstantinopoulos, P. A., Karamouzis, M. V., & Papavassiliou, A. G. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.07.002 · Cited by 33
Darbepoietin Alfa Potentiates the Efficacy of Radiation Therapy in Mice with Corrected or Uncorrected Anemia
Ning, S., Hartley, C. A., Molineux, G., & Knox, S. J. (2005) · Cancer Research · doi:10.1158/0008-5472.284.65.1 · Cited by 33
Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia
Herrington, J. D., Davidson, S. L., Tomita, D. K., Green, L., Smith, R. E., & Boccia, R. V. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.1.54 · Cited by 33
Intravenous administration of darbepoetin to NICU patients
Warwood, T. L., Ohls, R. K., Lambert, D. K., Jones, C., Scoffield, S. H., Gupta, N., Veng‐Pedersen, P., & Christensen, R. D. (2006) · Journal of Perinatology · doi:10.1038/sj.jp.7211498 · Cited by 32
Neuroprotective potential of erythropoietin and darbepoetin alfa in an experimental model of sciatic nerve injury
Grasso, G., Meli, F., Fodale, V., Calapai, G., Buemi, M., & Iacopino, D. G. (2007) · Journal of Neurosurgery Spine · doi:10.3171/spi-07/12/645 · Cited by 31
Molecular Design, Expression and Evaluation of PASylated Human Recombinant Erythropoietin with Enhanced Functional Properties
Hedayati, M. H., Norouzian, D., Aminian, M., Teimourian, S., Cohan, R. A., Sardari, S., & Khorramizadeh, M. R. (2017) · The Protein Journal · doi:10.1007/s10930-017-9699-9 · Cited by 31
Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma
Shannon, A. M., Bouchier‐Hayes, D. J., Condron, C. M., & Toomey, D. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602685 · Cited by 31
Sugar coating extends half-lives and improves effectiveness of cytokine hormones
Koury, M. J. (2003) · Trends in biotechnology · doi:10.1016/j.tibtech.2003.09.002 · Cited by 30
Glycomics in Human Diseases and Its Emerging Role in Biomarker Discovery
Onigbinde, S. B., Adeniyi, M., Daramola, O. E., Chukwubueze, F. M., Bhuiyan, M. M. A. A., Nwaiwu, J. I., Bhattacharjee, T., & Mechref, Y. S. (2025) · Biomedicines · doi:10.3390/biomedicines13082034 · Cited by 36
Kinetics of haematopoietic recovery after dose‐intensive chemo/radiotherapy in mice: optimized erythroid support with darbepoetin alpha
Hartley, C. A., Elliott, S., Begley, C. G., McElroy, P. L., Sutherland, W., Khaja, R., Heatherington, A. C., Graves, T., Schultz, H., del Castillo, J. M. G., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04467.x · Cited by 28
The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs
Fiocchi, E. H., Cowgill, L. D., Brown, D. C., Markovich, J. E., TUCKER, S. M., Labato, M. A., & Callan, M. B. (2017) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.14681 · Cited by 29
Increased Site 1 Affinity Improves Biopotency of Porcine Growth Hormone
Wan, Y., McDevitt, A., Shen, B., Smythe, M. L., & Waters, M. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406092200 · Cited by 28
Erythropoietin and co.: intrinsic structure and functional disorder
Uversky, V. N., & Redwan, E. M. M. M. (2016) · Molecular BioSystems · doi:10.1039/c6mb00657d · Cited by 28
Detection window of Darbepoetin-α following one single subcutaneous injection
Lamon, S., Robinson, N., Mangin, P. J., & Saugy, M. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.01.014 · Cited by 27
Anti-glycophorin single-chain Fv fusion to low-affinity mutant erythropoietin improves red blood cell-lineage specificity
Taylor, N. D., Way, J. C., Silver, P. A., & Cironi, P. (2010) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp085 · Cited by 26
Applying quality by design to glycoprotein therapeutics: experimental and computational efforts of process control
Jedrzejewski, P., del Val, I. J., Polizzi, K. M., & Kontoravdi, C. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.4 · Cited by 27
Erythropoietin and erythropoiesis stimulating agents
Debeljak, N., & Sytkowski, A. J. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1341 · Cited by 26
Update on the current management of newborns with neonatal encephalopathy
Wachtel, E. V., Verma, S., & Mally, P. (2019) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2019.07.001 · Cited by 26
Erythropoietin pharmacology
Jurado, J. M., Sánchez, E. T., Olmos, D., & Alba, E. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0128-y · Cited by 26
Fc-GDF15 glyco-engineering and receptor binding affinity optimization for body weight regulation
Fung, E., Kang, L., Sapashnik, D., Benard, S., Sievers, A., Liu, Y., Yan, G. G., Zhou, J. W., Rodriguez, L., Ma, W., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87959-5 · Cited by 24
Technologies for glycomic characterization of biopharmaceutical erythropoietins
Hua, S. S., Oh, M. J., Özcan, S., Seo, Y. S., Grimm, R., & An, H. J. (2015) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2015.02.004 · Cited by 25
Carbohydrate clearance receptors in transfusion medicine
Sørensen, A. L. T., Clausen, H., & Wandall, H. H. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.07.008 · Cited by 25
Improvement of in vitro stability and pharmacokinetics of hIFN-α by fusing the carboxyl-terminal peptide of hCG β-subunit
Ceaglio, N., Gugliotta, A., Tardivo, M. B., Cravero, D., Etcheverrigaray, M., Kratje, R. B., & Oggero, M. (2016) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2016.01.018 · Cited by 25
Improving the Pharmacodynamics and In Vivo Activity of ENPP1‐Fc Through Protein and Glycosylation Engineering
Stabach, P. R., Zimmerman, K., Adame, A., Kavanagh, D., Saeui, C. T., Agatemor, C., Gray, S. D., Cao, W., Cruz, E. M. D. L., Yarema, K. J., et al. (2020) · Clinical and Translational Science · doi:10.1111/cts.12887 · Cited by 25
Darbepoetin Alfa Treatment for Post-Renal Transplantation Anemia During Pregnancy
Goshorn, J., & Youell, T. D. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.07.047 · Cited by 25
Efficacy and immunogenicity of novel erythropoietic agents and conventional rhEPO in rats with renal insufficiency
Tillmann, H. C., Kuhn, B., Kränzlin, B., Sadick, M., Gross, J. P., Gretz, N., & Pill, J. (2005) · Kidney International · doi:10.1038/sj.ki.5000006 · Cited by 25
Erythropoiesis-Stimulating Agents
Elliott, S. (2010) · Cancer treatment and research · doi:10.1007/978-1-4419-7073-2_4 · Cited by 24
Soluble expression and partial purification of recombinant human erythropoietin from E. coli
Jeong, T.-H., Son, Y., Ryu, H.-B., Koo, B.-K., Jeong, S.-M., Hoang, P., Do, B. H., Song, J.-A., Chong, S.-H., Robinson, R. C., et al. (2014) · Protein Expression and Purification · doi:10.1016/j.pep.2014.01.001 · Cited by 24
Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli
Wang, Y., Liu, Y., Chen, J., Hao, S.-J., Hu, T., Ma, G., & Su, Z. G. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.11.016 · Cited by 24
Exposure‐Response Modeling of Darbepoetin Alfa in Anemic Patients With Chronic Kidney Disease Not Receiving Dialysis
Doshi, S., Chow, A. T., & Ruixo, J. J. P. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010377201 · Cited by 24
Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia
Hernández, E., Ganly, P. S., Charu, V., DiBenedetto, J., Tomita, D. K., Lillie, T., Taylor, K. M., & for the ARANESP 20030232 Study Group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903084164 · Cited by 23
A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC
Gascón, P., Nagarkar, R. V., Šmakal, M., Syrigos, K. N., Barrios, C. H., Sánchez, J. C., Zhang, L., Henry, D. H., Gordon, D., Hirsh, V., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.005 · Cited by 23
Strategies for Engineering Protein N-Glycosylation Pathways in Mammalian Cells
Wang, Q., Stuczynski, M. C., Gao, Y., & Betenbaugh, M. J. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2760-9_20 · Cited by 27
Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve
Duh, M. S., Lefèbvre, P., Fastenau, J. M., Piech, C. T., & Waltzman, R. J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-6-438 · Cited by 23
MicroPlate Sialyltransferase Assay: A Rapid and Sensitive Assay Based on an Unnatural Sialic Acid Donor and Bioorthogonal Chemistry
Noël, M., Gilormini, P., Cogez, V., Lion, C. J., Biot, C., Harduin‐Lepers, A., & Guérardel, Y. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00529 · Cited by 22
Assessment of the metabolism of therapeutic proteins and antibodies
Ezan, É., Bécher, F., & Fenaille, F. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.925878 · Cited by 22
Clinical Pharmacokinetics and Pharmacodynamics of Erythropoiesis-Stimulating Agents
Doshi, S., Krzyżański, W., Yue, S. V., Elliott, S. G., Chow, A. T., & Ruixo, J. J. P. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0098-x · Cited by 21
Targeted erythropoietin selectively stimulates red blood cell expansion in vivo
Burrill, D. R., Vernet, A., Collins, J. J., Silver, P. A., & Way, J. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525388113 · Cited by 19
Carbohydrate synthesis and biosynthesis technologies for cracking of the glycan code: Recent advances
Mrázek, H., Weignerová, L., Bojarová, P., Novák, P., Vaněk, O., & Bezouška, K. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.03.008 · Cited by 22
Preclinical Safety and Pharmacology of Hematide™, a Peptidic Erythropoiesis Stimulating Agent (ESA), in Rats and Monkeys
Woodburn, K. W., Schatz, P. J., Fong, K. L., Wilson, S. D., Ferrell, T., Spainhour, C. B., & Norton, D. (2008) · Drug and Chemical Toxicology · doi:10.1080/01480540701873186 · Cited by 21
Exploring a combined Escherichia coli-based glycosylation and in vitro transglycosylation approach for expression of glycosylated interferon alpha
Prabhu, S. K., Yang, Q., Tong, X., & Wang, L. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116037 · Cited by 20
Development of a suitable manufacturing process for production of a bioactive recombinant equine chorionic gonadotropin (reCG) in CHO-K1 cells
Villarraza, J., Antuña, S., Tardivo, M. B., Rodríguez, M. C., Mussio, P., Cattaneo, L., Fontana, D., Díaz, P. U., Ortega, H. H., Tríbulo, A., et al. (2021) · Theriogenology · doi:10.1016/j.theriogenology.2021.05.013 · Cited by 20
Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data
Carrera, F., Disney, A. P. S., & Molina, M. L. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm162 · Cited by 20
Detection of Darbepoetin Alfa Misuse in Urine and Blood
Mørkeberg, J., Lundby, C., Nissen-Lie, G., Nielsen, T. K., Hemmersbach, P., & Damsgaard, R. (2007) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31811e9d55 · Cited by 20
Darbepoetin, effective treatment of anaemia in paediatric patients with chronic renal failure
André, J.-L., Deschênes, G., Boudailliez, B. R., Broux, F., Fischbach, M., Gagnadoux, M., Horen, B., Lahoche-Manucci, A., Macher, M., Roussel, B., et al. (2007) · Pediatric Nephrology · doi:10.1007/s00467-006-0402-1 · Cited by 20
Urinary excretion of darbepoetin after intravenous vs subcutaneous administration to preterm neonates
Warwood, T. L., Ohls, R. K., Lambert, D. K., Leve, E. A., Veng‐Pedersen, P., & Christensen, R. D. (2006) · Journal of Perinatology · doi:10.1038/sj.jp.7211596 · Cited by 19
Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist
Pegg, C. L., Cooper, L. T., Zhao, J., Gerometta, M., Smith, F. M., Yeh, M. W., Bartlett, P. F., Gorman, J. J., & Boyd, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-06685-z · Cited by 19
Doping control of biosimilar epoetin kappa and other recombinant erythropoietins after intravenous application
Okano, M., Sato, M. P., Kaneko, E., & Kageyama, S. (2011) · Drug Testing and Analysis · doi:10.1002/dta.369 · Cited by 18
Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome
Bernieh, B., Abouchacra, S., Boobes, Y. A. R., Hakim, M., Nagelkerke, N. J. D., Chaaban, A., Ahmed, M., Hussain, Q., Eljack, H., Abayechi, F., et al. (2014) · International Urology and Nephrology · doi:10.1007/s11255-013-0640-7 · Cited by 18
Long-acting erythropoietin: clinical studies and potential uses in neonates
Ohls, R. K., & Dai, A. (2004) · Clinics in Perinatology · doi:10.1016/j.clp.2004.03.006 · Cited by 18
Empirical Methods to Calculate an Erythropoiesis-Stimulating Agent Dose Conversion Ratio in Nondialyzed Patients with Chronic Kidney Disease
Horowitz, J., Agarwal, A. K., Huang, F., Gitlin, M., Gandra, S. R., & Cangialose, C. B. (2009) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2009.15.9.741 · Cited by 18
Implementation of Glycan Remodeling to Plant-Made Therapeutic Antibodies
Bennett, L. D., Yang, Q., Berquist, B. R., Giddens, J. P., Ren, Z., Kommineni, V., Murray, R. C., White, E. L., Holtz, B. R., Wang, L., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020421 · Cited by 18
Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach
Moradi, Z., Maali, A., Shad, J. S., Farasat, A., Kouchaki, R., Moghadami, M., Ahmadi, M., & Azad, M. (2019) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-019-01170-1 · Cited by 19
The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis
Abu‐Alfa, A. K., Sloan, L. A., Charytan, C., Sekkarie, M. A., Scarlata, D., GLOBE, D. R., & Audhya, P. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x280653 · Cited by 18
Highly sensitive capillary electrophoresis analysis of N‐linked oligosaccharides in glycoproteins following fluorescence derivatization with rhodamine 110 and laser‐induced fluorescence detection
Ijiri, S., Todoroki, K., Yoshida, H., Yoshitake, T., Nohta, H., & Yamaguchi, M. (2011) · Electrophoresis · doi:10.1002/elps.201100258 · Cited by 17
Darbepoetin Alfa Administration to Achieve and Maintain Target Hemoglobin Levels for 1 Year in Patients With Chronic Kidney Disease
Hertel, J., Locay, H. R., Scarlata, D., Prathikanti, R., & Audhya, P. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.9.1188 · Cited by 17
Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings
Siegel, J., Jorgenson, J. A., Johnson, P. E., Brophy, D. F., Comstock, T. J., Feng, A., & Audhya, P. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070526 · Cited by 17
Additional N-glycosylation in the N-terminal region of recombinant human alpha-1 antitrypsin enhances the circulatory half-life in Sprague-Dawley rats
Chung, H.-S., Kim, J., Lee, S. M., & Park, S. J. (2016) · Glycoconjugate Journal · doi:10.1007/s10719-016-9657-3 · Cited by 17
Identification of the long-acting erythropoiesis-stimulating agent darbepoetin alfa in human urine by liquid chromatography–tandem mass spectrometry
Okano, M., Sato, M. P., & Kageyama, S. (2013) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-013-6836-y · Cited by 16
Erythropoietic Agents and the Elderly
Agarwal, N., & Prchal, J. T. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.06.007 · Cited by 16
Costs Associated with Erythropoiesis-Stimulating Agent Administration to Hemodialysis Patients
Churchill, D. N., Macarios, D., Attard, C. L., Kallich, J. D., & Goeree, R. A. (2007) · Nephron Clinical Practice · doi:10.1159/000104431 · Cited by 16
Comparison of Epoetin Alfa and Darbepoetin Alfa Biological Activity under Different Administration Schedules in Normal Mice
Sasu, B. J., Hartley, C. A., Schultz, H., McElroy, P. L., Khaja, R., Elliott, S. G., Egrie, J. C., Browne, J. K., Begley, C. G., & Molineux, G. (2005) · Acta Haematologica · doi:10.1159/000084446 · Cited by 16
Self-citation
Erythropoietic stimulating agents
Testa, U. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903499273 · Cited by 17
Pharmacokinetics of Darbepoetin Alfa after Intravenous or Subcutaneous Administration in Patients with Non-myeloid Malignancies Undergoing Chemotherapy
Heatherington, A. C., Dittrich, C., Sullivan, J. T., Rossi, G., & Schueller, J. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645020-00005 · Cited by 16
Chemo-enzymatic synthesis of glycosylated insulin using a GlcNAc tag
Tomabechi, Y., Suzuki, R., Haneda, K., & Inazu, T. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.12.031 · Cited by 16
Once-Monthly Darbepoetin alfa for Maintaining Hemoglobin Levels in Older Patients With Chronic Kidney Disease
AGARWAL, A., SILVER, M., Walczyk, M. H., Liu, W., & Audhya, P. (2006) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2006.07.007 · Cited by 16
A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia
Justice, G. R., Kessler, J. F., Jadeja, J., Campos, L. T., Weick, J. K., Chen, C.-F., Heatherington, A. C., & Amado, R. G. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi218 · Cited by 16
Assessment of rhEPO in Pharmaceutical Formulations by a Reversed‐Phase Liquid Chromatography Method and Bioassay
Barth, T., Sangoi, M. D. S., da Silva, L. M., Ferretto, R. M., & Dalmora, S. L. (2007) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826070701274668 · Cited by 15
Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development
Reynolds, T., de Zafra, C., Kim, A., & Gelzleichter, T. R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394810-6.00001-0 · Cited by 16
The Effects of Potential Neuroprotective Agents on Rat Facial Function Recovery Following Facial Nerve Injury
Vakharia, K. T., Lindsay, R. W., Knox, C., Edwards, C., Henstrom, D. K., Weinberg, J. S., Hadlock, T. A., & Heaton, J. T. (2010) · Otolaryngology · doi:10.1177/0194599810390892 · Cited by 15

Authors: Egrie, J. C., Dwyer, E., Browne, J. K., Hitz, A., & Lykos, M. A.
Affiliations: Amgen (United States) (US)
Corresponding author: Egrie, Joan C
Venue: Experimental Hematology
Publisher: Elsevier BV
Published: 2003-04
Volume: 31
Issue: 4
Pages: 290-299
ISSN: 0301-472X (ISSN-L)
DOI: 10.1016/s0301-472x(03)00006-7
OpenAlex: W2169177790
Cited by: 421
References: 47
Citations by year: 2026: 10 · 2025: 14 · 2024: 6 · 2023: 7 · 2022: 11 · 2021: 12 · 2020: 3 · 2019: 12 · 2018: 14 · 2017: 12 · 2016: 13 · 2015: 19 · 2014: 16 · 2013: 16 · 2012: 19
FWCI: 16.09
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 7008 d)
Locations: Experimental Hematology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
Keywords: darbepoetin alfa, recombinant human erythropoietin, erythropoietin analogues, hyperglycosylation, serum half-life, in vivo potency, hematocrit, dosing frequency, pharmacokinetics, pharmacodynamics
MeSH terms: Darbepoetin alfa, Animals, Carbohydrates, Dogs, Dose-Response Relationship, Drug, Electrochemistry, Electrophoresis, Polyacrylamide Gel, Erythropoietin, Half-Life, Hematocrit, Humans, Kinetics, Male, Molecular Weight, Recombinant Proteins, Rats, Sprague-Dawley, Receptors, Erythropoietin, N-Acetylneuraminic Acid, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks